Sign in
TerminatedNo phase

Real-World Study of Ceftazidime Avibactam in China

Key facts

Who runs it
Pfizer
Where
China17 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
220 people enrolled
Started
20 Oct 2022
Ended
11 Jul 2024
Type of study
Observational
Treatments tested
  • ceftazidime avibactam group
Record updated
4 September 2025
Why it stopped
The study was prematurely discontinued due to slow enrollment and strategic considerations. This decision was not based on any safety or efficacy concerns.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Initiate ≥1 dose of ceftazidime-avibactam during hospitalization
  • Aged ≥ 18 years old at the time of the informed consent signature
  • Provide signed informed consent. Exclusion criteria:
  • Are enrolled in any clinical trial, including enrollment in non interventional studies
  • Pregnant women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.

The group in the trial

  • ceftazidime avibactam group

    Receive ≥1 dose of ceftazidime avibactam in routine practice; Aged ≥ 18 years old at the time of the informed consent signature.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Real-World Study of Ceftazidime-Avibactam to Characterize the Usage in Clinical Practice
Record updated
4 September 2025